|
|
||||||||
Ann Thorac Surg 2007;83:1737-1743
© 2007 The Society of Thoracic Surgeons
a Departments of Thoracic and Cardiovascular Surgery, St. Lukes Medical Center, Milwaukee, Wisconsin
c Department of Laboratory Medicine, St. Lukes Medical Center, Milwaukee, Wisconsin
d Department of Internal Medicine, Section of Hematology/Oncology, St. Lukes Medical Center, Milwaukee, Wisconsin
e Department of Quality Management, St. Lukes Medical Center, Milwaukee, Wisconsin
f Department of Cardiovascular Research, St. Lukes Medical Center, Milwaukee, Wisconsin
b Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina
Accepted for publication December 11, 2006.
* Address correspondence to Dr Kress, Midwest Heart Surgery Institute, Ltd, 2901 W. Kinnickinnic River Pkwy, Suite 511, Milwaukee, WI 53215 (Email: dkress2003{at}msn.com).
Background: Given the large number of patients undergoing cardiac operations annually, it is important to identify populations at high risk for adverse outcomes. This observational study was conducted to determine the incidence of preoperative heparin-platelet factor 4 (HPF4) antibodies and to assess the associated risk of postoperative adverse outcomes in a nonselected cardiac surgery patient population.
Methods: Between March 2002 and December 2004, 1114 (92%) of 1209 patients undergoing cardiac surgery with heparin were tested in an unselected manner for HPF4 antibodies. Main outcome measures were HPF4 antibody seropositivity and fatal and nonfatal adverse clinical outcomes after cardiac surgery.
Results: Of those screened, 60 (5.4%) of 1114 had positive HPF4 antibodies preoperatively. These patients had longer mean postoperative length of stay (14.0 days versus 9.8 days, p = 0.05), a higher incidence of prolonged (
96 hours) mechanical ventilation (20.3% versus 9.2%, p = 0.02), acute limb ischemia (5.1% versus 0.9%, p = 0.03), renal complications including dialysis (20.3% versus 10.5%, p = 0.03), and gastrointestinal complications (15.3% versus 5.9%, p = 0.01). Stepwise logistic regression analysis showed positive HPF4 antibody status to be an independent predictor for adverse outcome and was associated with a higher risk for renal complications, including dialysis (adjusted odds ratio 2.2; 95% confidence interval, 1.1 to 4.3), than was diabetes.
Conclusions: In this large patient series, the presence of HPF4 antibodies before surgical heparin administration was an independent and clinically significant risk factor for postoperative adverse events after cardiac surgery. An optimal preoperative cardiac surgery risk profile should include HPF4 antibody status.
This article has been cited by other articles:
![]() |
D. Paparella, G. Scrascia, A. Galeone, M. Coviello, G. Cappabianca, M. T. Venneri, B. Favoino, M. Quaranta, L. de Luca Tupputi Schinosa, and T. E. Warkentin Formation of anti-platelet factor 4/heparin antibodies after cardiac surgery: influence of perioperative platelet activation, the inflammatory response, and histocompatibility leukocyte antigen status. J. Thorac. Cardiovasc. Surg., December 1, 2008; 136(6): 1456 - 1463. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Greinacher and J. H. Levy HIT Happens: Diagnosing and Evaluating the Patient with Heparin-Induced Thrombocytopenia Anesth. Analg., August 1, 2008; 107(2): 356 - 358. [Full Text] [PDF] |
||||
![]() |
M. P. Mullen, D. L. Wessel, K. C. Thomas, K. Gauvreau, E. J. Neufeld, F. X. McGowan Jr, and J. A. DiNardo The Incidence and Implications of Anti-Heparin-Platelet Factor 4 Antibody Formation in a Pediatric Cardiac Surgical Population Anesth. Analg., August 1, 2008; 107(2): 371 - 378. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Dellaria, P. E. Greilich, and R. Sarode Urgent Cardiac Surgery in a Patient with a Remote History of Heparin-Induced Thrombocytopenia: Use of the Anti-PF4/Heparin ELISA Confirmatory Test Anesth. Analg., August 1, 2008; 107(2): 379 - 381. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. E Dager Considerations for Drug Dosing Post Coronary Artery Bypass Graft Surgery Ann. Pharmacother., March 1, 2008; 42(3): 421 - 424. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Apostolidou, M. F. Sweeney, E. Missov, L. D. Joyce, R. John, and R. C. Prielipp Acute Left Atrial Thrombus After Recombinant Factor VIIa Administration During Left Ventricular Assist Device Implantation in a Patient with Heparin-Induced Thrombocytopenia Anesth. Analg., February 1, 2008; 106(2): 404 - 408. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |